• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Secondary analysis confirms safety of blood thinning agent
(American Heart Association) The blood thinner apixaban, which treats and prevents blood clots in some people with irregular heart rhythm, is safe and effective in stroke patients. Apixaban is associated with less bleeding, death and hospitalization than warfarin.
Source: EurekAlert! - Medicine and Health - February 21, 2020 Category: International Medicine & Public Health Source Type: news

Barriers to using stroke-preventing anticoagulants in Canada hinder appropriate management of patients with atrial fibrillation
(Elsevier) International guidelines recommend direct oral anticoagulants (DOACs) over warfarin to prevent stroke for most patients with atrial fibrillation (AF). However, a substantial portion of patients in Canada, who would benefit from anticoagulation, do not receive it adequately or at all. Experts review the evidence for the use of DOACs in the Canadian Journal of Cardiology, discuss reasons for the large gap between guidelines and clinical practice, including policy and funding barriers, and propose strategies for the future.
Source: EurekAlert! - Medicine and Health - November 5, 2018 Category: International Medicine & Public Health Source Type: news

Apixaban is a safe alternative to warfarin during catheter ablation of atrial fibrillation
(European Society of Cardiology) Apixaban and warfarin are equally safe during catheter ablation of atrial fibrillation, according to results of the AXAFA-AFNET 5 trial presented today in a late-breaking trial session at EHRA 2018, a European Society of Cardiology (ESC) congress.1 There were similar rates of stroke and bleeding, and an improvement in cognitive function was shown for the first time.
Source: EurekAlert! - Medicine and Health - March 20, 2018 Category: International Medicine & Public Health Source Type: news

Apixaban lowers stroke risk in AF patients undergoing cardioversion (EMANATE)
(European Society of Cardiology) Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-na ï ve patients with atrial fibrillation scheduled for elective cardioversion, according to late-breaking results from the EMANATE trial presented today in a Hot Line LBCT Session at ESC Congress. Rates of bleeding were similar between the two groups.
Source: EurekAlert! - Medicine and Health - August 28, 2017 Category: International Medicine & Public Health Source Type: news

How safe and effective are new drugs for stroke prevention?
(Mayo Clinic) For decades, warfarin was the only oral blood thinner available to reduce the risk of stroke for patients with atrial fibrillation. Warfarin use is cumbersome, because it requires ongoing blood test to monitor the effect and has numerous drug and food interaction. Now a number of non-vitamin K antagonist oral anticoagulant drugs are available for patients with atrial fibrillation and claim to revolutionize the care for patients with atrial fibrillation.
Source: EurekAlert! - Medicine and Health - October 3, 2016 Category: Global & Universal Source Type: news

New oral anticoagulants provide same stroke prevention as warfarin but cause less bleeding
(European Society of Cardiology) The new oral anticoagulants provide the same stroke prevention as warfarin but cause less intracranial bleeding, reports an observational study in more than 43,000 patients presented at ESC Congress 2016 today by Dr. Laila Staerk, a research fellow at Herlev and Gentofte University Hospital, Denmark.
Source: EurekAlert! - Medicine and Health - August 27, 2016 Category: Global & Universal Source Type: news

Mount Sinai's Dr. Reddy demonstrates cost-effectiveness of Watchman device
(The Mount Sinai Hospital / Mount Sinai School of Medicine) Long-term analysis shows cost-effectiveness of WATCHMAN left atrial appendage closure device over warfarin and NOACs in reducing stroke risk in non-valvular atrial fibrillation patients.
Source: EurekAlert! - Medicine and Health - December 21, 2015 Category: Global & Universal Source Type: news

Device's potential as alternative to warfarin for stroke prevention in patients with a-fib
(The JAMA Network Journals) Vivek Y. Reddy, M.D., of the Icahn School of Medicine at Mount Sinai, New York, and colleagues examined the long-term efficacy and safety, compared to warfarin, of a device to achieve left atrial appendage closure in patients with atrial fibrillation. The study appears in the Nov. 19 issue of JAMA, a cardiovascular disease theme issue.
Source: EurekAlert! - Medicine and Health - November 16, 2014 Category: Global & Universal Source Type: news